EIGHTH Gynaecological Cancer Academy

WORKSHOP

Baveno (Italy), September 30th and October 1st 2016

VENUE

DINO Hotel
Corso Giuseppe Garibaldi, 20
28831 Baveno (Italy)

This GCA Initiative is possible thanks to generous educational grant from Roche and AstraZeneca.
Friday September 30th 2016

GCA NETWORK WORKSHOP

15:30 - 16:00 Welcome coffee

16:00 - 16:10 Welcome and Introduction
Prof. Nicoletta Colombo - European Institute of Oncology, Milan (Italy)

16:10 - 17:30 BEYOND OVARIAN CANCER
16:10 - 16:30 CERVICAL CANCER: WHAT DO WE KNOW? WHAT DON'T WE KNOW? WHAT SHOULD BE INVESTIGATED?
Prof. Christian Marth - Universitätskliniken LKH, Innsbruck (Austria)
16:30 - 16:50 UTERINE SARCOMA: WHAT DO WE KNOW? WHAT DON'T WE KNOW? WHAT SHOULD BE INVESTIGATED?
Prof. Andrés Poveda - Instituto Valenciano de Oncología, Valencia (Spain)
16:50 - 17:10 ENDOMETRIAL CANCER: WHAT DO WE KNOW? WHAT DON'T WE KNOW? WHAT SHOULD BE INVESTIGATED?
Prof. Eric Pujade-Lauraine - Hôpital Hôtel Dieu, Paris (France)
17:10 - 17:30 VULVAR CANCER: WHAT DO WE KNOW? WHAT DON'T WE KNOW? WHAT SHOULD BE INVESTIGATED?
Dr. Fabio Landoni - European Institute of Oncology, Milan (Italy)

17:30 - 17:50 Discussion

17:50 - 18:00 BREAK

18:00 - 19:00 WORKSHOP SESSION 1 (4 TABLES)
Table 1: Define the most important missing information in cervical cancer and design a trial to answer the relevant question
Prof. Jonathan Ledermann - University College London Cancer Institute, London (UK)
Prof. Nicoletta Colombo - European Institute of Oncology, Milan (Italy)
Table 2: Define the most important missing information in vulvar cancer and design a trial to answer the relevant question
Prof. Christian Marth - Universitätskliniken LKH, Innsbruck (Austria)
Dr. Fabio Landoni - European Institute of Oncology, Milan (Italy)
Table 3: Define the most important missing information in uterine sarcoma and design a trial to answer the relevant question
Prof. Andrés Poveda - Instituto Valenciano de Oncología, Valencia (Spain)
Prof. Nicoletta Colombo - European Institute of Oncology, Milan (Italy)
Table 4: Define the most important missing information in endometrial cancer and design a trial to answer the relevant question
Prof. Cristina Sessa - Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona (Switzerland)
Prof. Eric Pujade-Lauraine - Hôpital Hôtel Dieu, Paris (France)

19:00 - 20:00 PRESENTATION OF RESULTS BY EACH TABLE AND DISCUSSION

20:30 - 22:30 GROUP DINNER AT THE HOTEL

Saturday, October 1st 2016

JOINT WORKSHOP GCA & PHI-2 NETWORKS

08:30 - 10:30 BEYOND CLINICAL EXPERTISE: FUNDAMENTALS OF CLINICAL TRIAL METHODOLOGY
08:30 - 09.15 STATISTICAL PLANS, INTERIM ANALYSIS AND SUBGROUP ANALYSIS
Prof. Paolo Bruzzi - IRCCS Azienda Ospedaliera Universitaria San Martino IST, Genova (Italy)
09.15 - 09.30 PHASE 1/II: WHAT INFORMATION CAN WE DERIVE? RATIONAL, DESIGN AND OBJECTIVES
Prof. Cristina Sessa - Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona (Switzerland)
09.30 - 10.15 SURROGATE ENDPOINTS
Prof. Paolo Bruzzi - IRCCS Azienda Ospedaliera Universitaria San Martino IST, Genova (Italy)
10.15 - 10.30 PHASE 2: WHAT INFORMATION CAN WE DERIVE? RATIONAL, DESIGN AND OBJECTIVES
Prof. Jonathan Ledermann - University College London Cancer Institute, London (UK)
10.30 - 10.50 Discussion

10.50 - 11.00 BREAK

11.00 - 12.00 WORKSHOP SESSION 2 (6 TABLES)
Table 1: Analysis of a published Phase III trial: define whether the statistical design, the sample size, the expected benefit, the statistical analysis and the conclusion are appropriate
Prof. Christian Marth - Universitätskliniken LKH, Innsbruck (Austria)
Table 2: Analysis of a published Phase II trial: define whether the statistical design, the sample size, the expected benefit the statistical analysis and the conclusion are appropriate
Prof. Cristina Sessa - Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona (Switzerland)
Prof. Eric Pujade-Lauraine - Hôpital Hôtel Dieu, Paris (France)
Table 3: Analysis of a published Phase I trial: define whether the statistical design, the sample size, the expected outcome, the statistical analysis and the conclusion are appropriate
Prof. Jonathan Ledermann - University College London Cancer Institute, London (UK)
Table 4: A published subgroup analysis of a Phase III trial: define whether the statistical plan, the choice of subgroups, the statistical analysis and the conclusion are appropriate
Prof. Andrés Poveda - Instituto Valenciano de Oncología, Valencia (Spain)
Dr. Nicole Concin - Innsbruck Medical University, Innsbruck (Austria)
Table 5: A published trial of a meta-analysis: define whether the methodology, the sample size, the expected outcome, the statistical analysis and the conclusion are appropriate
Prof. Paolo Bruzzi - IRCCS Azienda Ospedaliera Universitaria San Martino IST, Genova (Italy)
Prof. Nicoletta Colombo - European Institute of Oncology, Milan (Italy)
Table 6: A published trial with surrogate endpoints: define whether the statistical plan, the expected outcome, the statistical analysis and the conclusion are appropriate
Prof. Antonio Casado - Hospital Clinico San Carlos, Madrid (Spain)

12.00 - 13.00 DISCUSSION AND PRESENTATION OF RESULTS

13:00 LUNCH AND DEPARTURES